Subscribe To
Mirati (mrtx) expected to beat earnings estimates: what to know ahead of q4 release
Mirati (mrtx) possesses the right combination of the two key ingredients for a likely earnings beat in ...
February 21, 2022, 4:11 pm
Mirati (mrtx) down on longer review period for adagrasib nda
The FDA accepts Mirati's (mrtx) NDA for its lung cancer candidate, adagrasib. A decision is expected by...
February 17, 2022, 1:05 pm
Mirati (mrtx) down on longer review period for adagrasib nda
The FDA accepts Mirati's (mrtx) NDA for its lung cancer candidate, adagrasib. A decision is expected by...
February 17, 2022, 1:05 pm
Mirati (mrtx) down on longer review period for adagrasib nda
The FDA accepts Mirati's (mrtx) NDA for its lung cancer candidate, adagrasib. A decision is expected by...
February 17, 2022, 1:05 pm
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: mrtx) marketing application seeki...
February 16, 2022, 8:21 am
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: mrtx) marketing application seeki...
February 16, 2022, 8:21 am
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: mrtx) marketing application seeki...
February 16, 2022, 8:21 am
Mirati therapeutics to report fourth quarter and full year financial results for 2021 and recent corporate updates on february 28, 2022
SAN DIEGO , Feb. 14, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: mrtx), a clinical-stage ta...
February 14, 2022, 7:30 am
Mirati therapeutics to report fourth quarter and full year financial results for 2021 and recent corporate updates on february 28, 2022
SAN DIEGO , Feb. 14, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: mrtx), a clinical-stage ta...
February 14, 2022, 7:30 am
Mirati therapeutics to report fourth quarter and full year financial results for 2021 and recent corporate updates on february 28, 2022
SAN DIEGO , Feb. 14, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: mrtx), a clinical-stage ta...
February 14, 2022, 7:30 am
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: mrtx) has announced data from a Phase 2 cohort of the KRYSTAL-1 stud...
January 21, 2022, 12:14 pm
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: mrtx) has announced data from a Phase 2 cohort of the KRYSTAL-1 stud...
January 21, 2022, 12:14 pm
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: mrtx) has announced data from a Phase 2 cohort of the KRYSTAL-1 stud...
January 21, 2022, 12:14 pm